Dkt No. PP00362.102 USSN: 09/674,183 PATENT

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-4. (Cancelled)

- 5. (Currently amended) A carrier protein according to claim 4, that comprises a P23TT, P32TT, P21TT, PfCs PFT3, P30TT, P2TT, HBVnc, HA influenza hemagglutinin (HA), HbsAg and MT influenza matrix (MT) CD4+T cell epitopes.
- 6. (Currently amended) A <u>The</u> carrier protein according to claim 4 <u>5</u>, that <u>further</u> comprises a <u>P23TT</u>, <u>P32TT</u>, <u>P21TT</u>, <u>PfCs</u>, <u>P30TT</u>, <u>P2TT</u>, <u>HBVne</u>, <u>HA</u>, <u>HbsAg</u>, <u>MT-and</u> an hsp70 CD4+ T cell epitope.

7-12. (Cancelled)

- 13. (Currently amended) A The carrier protein according to claim 11 37, wherein the polysaccharide is from any one of the following organisms: S. pneumoniae, N. meningitidis, S. aureus, Klebsiella, or S. typhimurium.
- 14. (Currently amended) A <u>The</u> carrier protein according to claim 14 37, wherein the polysaccharide is conjugated to the carrier protein by a covalent linkage.

Dkt No. PP00362.102 USSN: 09/674,183 PATENT

15. (Currently amended) A The carrier protein according to claim 14 37, wherein the polysaccharide is conjugated to the carrier protein by reductive amination.

16-32. (Cancelled)

- 33. (Currently amended) A <u>The</u> carrier protein according to claim 5, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.
- 34. (Currently amended) A The carrier protein according to claim 6, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.
- 35. (Currently amended) A <u>The</u> carrier protein according to claim 5, wherein the carrier protein is in an oligomeric form.
- 36. (Currently amended) A <u>The</u> carrier protein according to claim 6, wherein the carrier protein is in an oligomeric form.
- 37. (Currently amended) A <u>The</u> carrier protein according to claim 5, conjugated to a polysaccharide.
- 38. (Currently amended) A The carrier protein according to claim 6, conjugated to a polysaccharide.
- 39. (Currently amended) A <u>The</u> carrier protein according to claim 37, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.
- 40. (Currently amended) A <u>The</u> carrier protein according to claim 38, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.

Dkt No. PP00362.102 USSN: 09/674,183 **PATENT**

- 41. (Previously presented) A vaccine comprising the carrier protein according to claim 5.
- 42. (Previously presented) A vaccine comprising the carrier protein according to claim 6.
- 43. (Previously presented) A vaccine comprising the carrier protein according to claim 39.
- 44. (Previously presented) A vaccine comprising the carrier protein according to claim 40.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
Потивъ

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.